

Unique Technology
Based on fully human synthetic phage/yeast display librairies

Best in class scientific expertise
International research team with over 100 years of combined expertise

Proprietary antibody
Outstanding human antibodies assets available for partnering and licensing

TECHNOLOGY
- Our core technology is based on the HuscI2™ suite of proprietary fully human synthetic antibody libraries combined to state-of-the-art in vitro antibody screening methods, based on robust and flexible display technologies powered by AI and ML.
- Mabqi’s antibody discovery platform is ideally suited for challenging targets such as:
- - Ion channels
- - Transmembrane proteins (GPCRs)
- - Soluble proteins
- - Peptides and much more
PIPELINE
Mabqi is developing a robust pipeline of innovative therapeutic antibodies in oncology.
Some of our lead candidates display unique pH-sensitive features and are readily convertible to next generation formats such as ADC, Tcell engagers (TCE), CAR-T therapies.


ANTIBODY DISCOVERY PLATFORM
-
Our advanced antibody discovery platform strengthens and accelerates antibody development by providing comprehensive support throughout the discovery process:
- High-throughput in vitro selection & screening
- Antibody hits generation
- Functional validation of fully human antibodies leads
ABOUT US
Mabqi is a biotechnology company with an integrated
approach to develop human antibodies.

LATEST NEWS
Dr JF Prost joins Mabqi leadership team as new Medical Director
Mabqi is thrilled to welcome Jean-François Prost, MD, as Acting Medical Director. With over 30 years of top management experience in...
New scientific paper published in mAbs, 2024
Mabqi is proud to co-author the scientific article « Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple...
Mabqi will be attending BIO EUROPE 2024
Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.